Phase I and pharmacokinetic trial of AP5346, a DACH–platinum–polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients

Author： Campone Mario   Rademaker-Lakhai Jeany   Bennouna Jaafar   Howell Stephen   Nowotnik David   Beijnen Jos   Schellens Jan  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.60, Iss.4, 2007-09, pp. : 523-533

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors

By Murakami H.   Kurata T.   Onozawa Y.   Watanabe J.   Ono A.   Takahashi T.   Yamamoto N.   Fujisaka Y.   Kiyota H.   Hayashi H.   Tanaka K.   Nakagawa K.   Kuroda S.  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 623-630

Springer Publishing Company

Access to resources Recommend Favorite

A phase I, pharmacokinetic and pharmacodynamic dose escalation trial of weekly paclitaxel with interferon-α2b in patients with solid tumors

By Schneider Bryan   Fukunaga Anna   Murry Daryl   Yoder Christy   Fife Karen   Foster Anne   Rosenberg Leslie   Kelich Stephanie   Li Lang   Sweeney Christopher  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 2, 2007-02 ,pp. : 261-268

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours

By de Jonge M.J.A.   Verweij J.   van der Gaast A.   Valota O.   Mora O.   Planting A.S.T.   Mantel M.A.   Bosch S.V.D.   Lechuga M.J.   Fiorentini F.   Hess D.   Sessa C.  

European Journal of Cancer, Vol. 38, Iss. 18, 2002-12 ,pp. : 2407-2415

Elsevier

Access to resources Recommend Favorite

Randomized Trial of Single Agent Paclitaxel Given Weekly Versus Every Three Weeks and with Peroral Versus Intravenous Steroid Premedication to Patients with Ovarian Cancer Previously Treated with Platinum

By Rosenberg Per   Andersson Ha˚kan   Boman Karin   Ridderheim Mona   Sorbe Bengt   Puistola Ulla   Parö Gunnar  

Acta Oncologica, Vol. 41, Iss. 5, 2002-09 ,pp. : 418-424

Informa Healthcare

Access to resources Recommend Favorite

A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan

By Verschraegen Claire   Kudelka Andrzej   Hu Wei   Vincent Monique   Kavanagh John   Loyer Evelyne   Bastien Luc   Duggal A.   Jager R.  

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 1, 2004-01 ,pp. : 1-7

Springer Publishing Company

Access to resources Recommend Favorite